Celestial Biolabs (Delisted) share news and announcements
BSE: 532871Pharmaceuticals & Biotechnology
Last traded ₹1.75 on 11 Mar 2020
Delisted on 16 Oct 2024.
Celestial Biolabs share news and announcements
634 announcements, routine notices left out, newest first. Page 5 of 13.
Apr 2019
19 Apr · Shareholding for the Period Ended March 31, 2019
Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click ....19 Apr · Statement Of Investor Complaints For The Quarter Ended March 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Feb 2019
18 Feb · Legal
Exchange has sought clarification from Celestial Biolabs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone limited review report not submitted. The response of the Company is awaited.
Jan 2019
17 Jan · Statement Of Investor Complaints For The Quarter Ended December 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 1 1 010 Jan · Shareholding for the Period Ended December 31, 2018
Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly Click ....
Nov 2018
14 Nov · Board meeting
Oct 2018
24 Oct · Compliance Certificate Under Reg.7(3) Of SEBI (LODR) Regulations, 2015
22 Oct · CERTIFICATE UNDER REGULATION 40 (9) OF SEBI (LODR) REGULATIONS, 2015
16 Oct · Shareholding for the Period Ended September 30, 2018
Shareholding Pattern for the Period Ended September 30, 2018. For more details, kindly Click ....16 Oct · Statement Of Investor Complaints For The Quarter Ended September 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 010 Oct · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....8 Oct · Updates
8 Oct · Business
Sep 2018
4 Sep · Board meeting
Aug 2018
29 Aug · Board meeting
23 Aug · Business
20 Aug · Legal
Exchange has sought clarification from Celestial Biolabs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Financial results not signed by authorized signatory/ies -3. Standalone limited review report not submitted. The response of the Company is awaited.
Jul 2018
18 Jul · Shareholding for the Period Ended June 30, 2018
Shareholding Pattern for the Period Ended June 30, 2018. For more details, kindly Click ....18 Jul · Statement Of Investor Complaints For The Quarter Ended June 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Jun 2018
1 Jun · Legal
Exchange has sought clarification from Celestial Biolabs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. -2. Standalone audited report not submitted. -3. Board meeting notice not submitted. -4. Standalone Reconciliation of Equity not submitted- 5. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
May 2018